摘要
目的探讨切除修复交叉互补基因1(ERCC1)在老年晚期非小细胞肺癌(NSCLC)组织中的表达情况及其临床意义。方法采用免疫组化法检测76例老年晚期NSCLC患者肿瘤组织中ERCC1的表达水平。结果 76例老年晚期非小细胞肺癌组织中ERCC1蛋白表达阳性率为36.84%,与患者性别、病理类型、分化程度、临床分期及吸烟指数无关;ERCC1表达阳性组化疗有效率(17.86%)低于阴性组(43.75%),差异有统计学意义(P<0.05);ERCC1表达阳性组中位生存期(MST)(10个月)短于阴性组(14个月),但差异无统计学意义(P>0.05)。结论 ERCC1蛋白表达水平是铂类药物化疗疗效的一个预测指标,有助于非小细胞肺癌个体化化疗方案的制定。
Objective To study the expression and clinical significance of excision repair cross-complementing group 1( ERCC1) in elderly patients with advanced non-small cell lung cancer( NSCLC). Methods The expression level of ERCC1 in76 advanced non-small cell lung cancer( NSCLC) patients were analyzed using immunohistochemical methods. Results The positive ERCC1 protein expression rate was 36. 84% among 76 cases,and there was no correlation with gender,pathology,differentiation degree,clinical stage and smoking index. The effect of chemotherapy in positive group( 17. 86%) was lower than that of negative group( 43. 75%) and the difference was statistically significant( P < 0. 05). The median survival time in positive group( 10months) was lower than that of negative group( 14 months),but the difference was not statistically significant( P > 0. 05). Conclusion The expression level of ERCC1 protein can be a predictive indicator for efficacy of platinum-based chemotherapy,and it is useful for the clinical development of chemotherapy program for NSCLC patients.
出处
《实用癌症杂志》
2015年第1期32-35,共4页
The Practical Journal of Cancer
关键词
ERCC1
非小细胞肺癌
老年
化疗
ERCC1
Non-small-cell lung cancer
Elderly
Chemotherapy
